Literature DB >> 23449600

Trichomonas vaginalis infection among women receiving gynaecological care at an Alabama HIV Clinic.

Christina A Muzny1, Charles A Rivers, Erika L Austin, Jane R Schwebke.   

Abstract

OBJECTIVE: Trichomoniasis vaginalis is a risk factor for the acquisition and transmission of HIV. The objective of this study was to determine the prevalence of T vaginalis (using culture) among HIV-infected women receiving gynaecological care at an university HIV clinic in Alabama in addition to predictors of infection.
METHODS: Electronic medical record review of women presenting to the clinic for gynaecological care during 2006-2012 was performed. Demographic and sexual history data was abstracted in addition to absolute CD4 cell count, HIV-1 viral load and sexually transmitted infection (STI) (including T vaginalis) testing results. Analysis was conducted using Stata V.12.
RESULTS: T vaginalis was prevalent in 17.4% (83/478) of HIV-infected women; other STIs were less prevalent. Among these women, 384 presented for routine STI screening, of which 12% (46/384) were T vaginalis-infected. Younger age, African-American race, lifetime history of tobacco and drug abuse, lack of HIV therapy, HIV-1 viral load >400 copies/ml, and report of seeking gynaecological care for reasons other than routine STI screening (ie, having symptoms) were significant predictors of T vaginalis in univariate analysis. Age, African American race, and report of seeking gynaecological care for reasons other than routine STI screening remained associated with T vaginalis in multivariable analysis.
CONCLUSIONS: T vaginalis remains highly prevalent among HIV-infected women, a proportion of which may be asymptomatic. If left undiagnosed and untreated, these women may be more likely to transmit HIV. Increased emphasis on screening for high risk sexual behaviours, testing for T vaginalis, and risk reduction counselling is necessary for all HIV-infected women.

Entities:  

Keywords:  CLINICAL STI CARE; HIV WOMEN; TRICHOMONAS

Mesh:

Year:  2013        PMID: 23449600     DOI: 10.1136/sextrans-2012-050889

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  5 in total

1.  Relationships between neighbourhood characteristics and current STI status among HIV-infected and HIV-uninfected women living in the Southern USA: a cross-sectional multilevel analysis.

Authors:  Danielle F Haley; Michael R Kramer; Adaora A Adimora; Regine Haardörfer; Gina M Wingood; Christina Ludema; Anna Rubtsova; DeMarc A Hickson; Zev Ross; Elizabeth Golub; Hector Bolivar; Hannah Lf Cooper
Journal:  Sex Transm Infect       Date:  2017-03-07       Impact factor: 3.519

Review 2.  Prevention of Sexually Transmitted Diseases in HIV-Infected Individuals.

Authors:  Laura Quilter; Shireesha Dhanireddy; Jeanne Marrazzo
Journal:  Curr HIV/AIDS Rep       Date:  2017-04       Impact factor: 5.071

3.  Gonorrhoea and chlamydia in persons with HIV: number needed to screen.

Authors:  Susan Tuddenham; Khalil G Ghanem; Kelly A Gebo; Richard D Moore; William Christopher Mathews; Allison Agwu; Kenneth Mayer; Christina Schumacher; Julia Raifman; Stephen A Berry
Journal:  Sex Transm Infect       Date:  2019-04-06       Impact factor: 3.519

4.  Clinical Evaluation of the Cepheid Xpert TV Assay for Detection of Trichomonas vaginalis with Prospectively Collected Specimens from Men and Women.

Authors:  Jane R Schwebke; C A Gaydos; T Davis; J Marrazzo; D Furgerson; S N Taylor; B Smith; L H Bachmann; R Ackerman; T Spurrell; D Ferris; C A Burnham; H Reno; J Lebed; D Eisenberg; P Kerndt; S Philip; J Jordan; N Quigley
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

5.  Trichomonas vaginalis infection and the diagnostic significance of detection tests among Ghanaian outpatients.

Authors:  Richard Harry Asmah; Rita Ofosuaa Agyeman; Noah Obeng-Nkrumah; Harriet Blankson; Georgina Awuah-Mensah; Momodou Cham; Listowell Asare; Patrick Ferdinand Ayeh-Kumi
Journal:  BMC Womens Health       Date:  2018-12-27       Impact factor: 2.809

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.